Bruker (NASDAQ:BRKR) Shares Pass Above Two Hundred Day Moving Average – What’s Next?
by Danessa Lincoln · The Markets DailyBruker Corporation (NASDAQ:BRKR – Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $39.00 and traded as high as $48.72. Bruker shares last traded at $48.44, with a volume of 1,316,616 shares traded.
Analyst Upgrades and Downgrades
Several research firms have weighed in on BRKR. Barclays raised their price objective on shares of Bruker from $45.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. UBS Group raised their price target on shares of Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. The Goldman Sachs Group initiated coverage on shares of Bruker in a research report on Tuesday, December 9th. They issued a “sell” rating and a $40.00 price objective for the company. Rothschild & Co Redburn initiated coverage on Bruker in a report on Thursday, November 20th. They set a “buy” rating and a $60.00 price objective on the stock. Finally, TD Cowen increased their price objective on Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $51.38.
Get Our Latest Research Report on Bruker
Bruker Stock Down 0.8%
The firm has a market cap of $7.16 billion, a P/E ratio of -294.44, a price-to-earnings-growth ratio of 6.99 and a beta of 1.17. The firm’s 50 day moving average is $44.34 and its two-hundred day moving average is $39.12. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81.
Bruker (NASDAQ:BRKR – Get Free Report) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.12. The company had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The business’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period last year, the business posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, research analysts anticipate that Bruker Corporation will post 2.69 EPS for the current fiscal year.
Bruker Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Stockholders of record on Monday, December 8th will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, December 8th. Bruker’s payout ratio is -125.00%.
Insider Activity
In related news, Director John A. Ornell sold 6,233 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the sale, the director directly owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. This represents a 15.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 27.30% of the company’s stock.
Institutional Investors Weigh In On Bruker
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Allworth Financial LP increased its holdings in Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Bruker by 63.0% during the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after buying an additional 347 shares during the period. UMB Bank n.a. boosted its position in shares of Bruker by 26.3% during the second quarter. UMB Bank n.a. now owns 1,673 shares of the medical research company’s stock worth $69,000 after buying an additional 348 shares during the period. Linden Thomas Advisory Services LLC grew its holdings in shares of Bruker by 2.1% during the third quarter. Linden Thomas Advisory Services LLC now owns 19,669 shares of the medical research company’s stock worth $639,000 after buying an additional 396 shares in the last quarter. Finally, M&T Bank Corp raised its position in Bruker by 2.7% in the 2nd quarter. M&T Bank Corp now owns 15,580 shares of the medical research company’s stock valued at $642,000 after buying an additional 411 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.
Bruker Company Profile
Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.
Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.
In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.